The share price doesn't have the scientific rigor of an FDA approved human clinical trial hosted at Harvard.
The data is the data. Price action is also data, but some will say reading it is like fortune telling.
So the whole idea is we make a bet that the market is incorrectly valuing what we buy.
IMO the CTIX share price is not even correctly factoring in the preliminary efficacy data from the Brilacidin trial. It's just at the "we have a Kevetrin trial dosing at Dana-Farber dosing" level. (December 2012)
Go figure...
So I'm not sure the share price proves that the data revealed to date is wrong. Just not enough to overcome the limitations of the increased selling pressure of the last few months and the OTC.
Dana-Farber's Dr Shapiro choosing to present a second poster on the same ongoing Phase 1 clinical trial proves to me we have something interesting here with Kevetrin. Much more so than the share price. He is the director of the Early Drug Development Center after all. He would have had other P1 trials to choose to present for the first time. Instead he does as second presentation of P1 Kevetrin mostly listing the information from the first presentation? To me it's obvious that he's calling unusual attention to Kevetrin.
To me it's suggestive that the few case studies indicating preliminary efficacy that we've heard about are not going to be the only ones. IMO a more reliable indicator than the share price. No proof of that, just an opinion; but I expect it indicates the company has not misrepresented the case studies presented so far. I don't think he'd allow that, what with two ASCO presentations and all.
Share price and scientific results have no correlation. Any experienced biotech investor has seen plenty of times when share price has been extremely high with few if any results, and other times that share price does not accurately reflect the value of the science.
Surely you know that the "efficient market" hypothesis has been shown to be wrong many times.